What the FDA labels say about taking them together
Methotrexate and oxaprozin
Oxaprozin's FDA label of December 26, 2024 names methotrexate in its drug interactions section; methotrexate's label does not name oxaprozin itself but warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)). The oxaprozin label: “Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity because NSAID administration may result in increased plasma levels of methotrexate, especially in patients receiving high doses …”
Check it at the source: the methotrexate FDA label on DailyMed (effective May 27, 2026, Accord Healthcare Inc.); the oxaprozin FDA label on DailyMed (effective December 26, 2024, Amneal Pharmaceuticals NY LLC).
What does the methotrexate label say about oxaprozin?
Methotrexate's label does not name oxaprozin itself; it warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)):
Methotrexate label, boxed warningUnexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia, and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with some nonsteroidal anti-inflammatory drugs (NSAIDs) [see Warnings and Precautions (5.1) and Drug Interactions(7.1) ].
Methotrexate label, drug interactionsConcomitant administration of some NSAIDs with high dose methotrexate therapy has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and gastrointestinal toxicity [see Warnings and Precautions (5.1) ].
Source: FDA drug label (Methotrexate), Accord Healthcare Inc., effective May 27, 2026 (SPL set 874c7f43-a3be-4236-89cc-24c44e3c5813), via openFDA; the full label on DailyMed
What does the oxaprozin label say about methotrexate?
Oxaprozin label, drug interactionsMethotrexate Clinical Impact: Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (…) because NSAID administration may result in increased plasma levels of methotrexate, especially in patients receiving high doses of methotrexate. Intervention: During concomitant use of oxaprozin and methotrexate, monitor patients for methotrexate toxicity.
Source: FDA drug label (Oxaprozin), Amneal Pharmaceuticals NY LLC, effective December 26, 2024 (SPL set d9b0ca6c-4c53-4f6e-918b-02a8c472a194), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Methotrexate | Oxaprozin | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Psoriasis, Leukemia, lymphoma and myeloma, Breast cancer | Osteoarthritis, Rheumatoid arthritis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.158 per tablet 2.5 mg tablet | $0.475 per tablet 600 mg tablet |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once